Navigation Links
Keryx Biopharmaceuticals Announces Positive Final Data from Zerenex™ Short-Term Phase 3 Study
Date:4/28/2011

otocol Assessment (SPA) agreement with the FDA, the Phase 3 clinical program for Zerenex consists of two clinical studies, the completed short-term study, and a long-term safety and efficacy study that is currently ongoing.

About Keryx Biopharmaceuticals, Inc. Keryx Biopharmaceuticals is focused on the acquisition, development and commercialization of medically important pharmaceutical products for the treatment of cancer and renal disease. Keryx is developing KRX-0401 (perifosine), a novel, potentially first-in-class, oral anti-cancer agent that inhibits Akt activation in the phosphoinositide 3-kinase (PI3K) pathway, and also affects a number of other key signal transduction pathways, including the JNK pathway, all of which are pathways associated with programmed cell death, cell growth, cell differentiation and cell survival. KRX-0401 has demonstrated both safety and clinical efficacy in several tumor types, both as a single agent and in combination with approved therapies. KRX-0401 is currently in Phase 3 clinical development for both refractory advanced colorectal cancer and multiple myeloma, and in Phase 1 and 2 clinical development for several other tumor types. Each of the KRX-0401 Phase 3 studies is being conducted under a Special Protocol Assessment (SPA) agreement with the FDA. Keryx is also developing Zerenex (ferric citrate), an oral, ferric iron-based compound that has the capacity to bind to phosphate and form non-absorbable complexes. The Phase 3 clinical program of Zerenex for the treatment for hyperphosphatemia (elevated phosphate levels) in patients with end-stage renal disease on dialysis is being conducted pursuant to an SPA agreement with the FDA. Keryx is headquartered in New York City.

Cautionary StatementSome of the statements included in this press release, particularly those anticipating future clinical trials and business prospects for Zerenex (ferric citrate) may be forward-looking statements that in
'/>"/>

SOURCE Keryx Biopharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related biology technology :

1. Keryx Biopharmaceuticals to Present at 13th Annual BIO CEO and Investor Conference
2. Keryx Biopharmaceuticals to Present at 29th Annual J.P. Morgan Healthcare Conference
3. Keryx Biopharmaceuticals to Present at Lazard Capital Markets 7th Annual Healthcare Conference
4. Keryx Biopharmaceuticals to Present at the UBS 2010 Global Life Sciences Conference
5. Æterna Zentaris Partner Keryx Announces Special Protocol Assessment Agreement with FDA for Phase 3 Trial of Perifosine (KRX-0401) in the Treatment of Patients with Refractory Metastatic Colorectal Cancer
6. Æterna Zentaris Partner Keryx Announces Positive Phase 2 Results for Perifosine as a Single Agent for the Treatment of Advanced Waldenstroms Macroglobulinemia
7. Æterna Zentaris Partner Keryx Reports a Statistically Significant Benefit in Survival from Updated Results of a Randomized, Double-Blind, Placebo-Controlled Phase 2 Study of Perifosine (KRX-0401) in the Treatment of Advanced Metastatic Colon Cancer
8. AEterna Zentaris Partner, Keryx, Initiates Phase 3 Registration Trial with Perifosine (KRX-0401) for the Treatment of Patients with Advanced Multiple Myeloma
9. AEterna Zentaris Partner, Keryx, Reports Updated Phase 1/2 Data, Including New Survival Data, on Perifosine (KRX-0401) in the Treatment of Advanced Multiple Myeloma at the 51st Annual Meeting of the American Society of Hematology
10. AEterna Zentaris Partner, Keryx Biopharmaceuticals, Receives Orphan-Drug Designation for Perifosine (KRX-0401) for the Treatment of Multiple Myeloma
11. Keryx Biopharmaceuticals, Inc. Announces Second Quarter 2009 Financial Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/31/2014)... , Oct. 31, 2014  Tavistock Development ... by Tavistock Group, celebrated the groundbreaking of the ... City. The 92,000-square-foot, three-story facility ... Central Florida designed specifically for life ... the heart of the 650-acre Lake Nona Medical ...
(Date:10/30/2014)... 2014  Ardelyx, Inc. (NASDAQ: ARDX ... gastrointestinal and metabolic diseases, today announced that it ... Thursday, November 6, 2014. Following the announcement, the ... call and webcast at 4:30pm ET to review ... update. The live webcast can be ...
(Date:10/30/2014)... SoundConnect , an industry leading ... end users the key to turning this already ... adding voice enablement and hybrid audio conferencing. , ... communication tool that includes presence, instant messaging and ... becomes a comprehensive unified communications solution. Adding the ...
(Date:10/30/2014)... (PRWEB) October 30, 2014 Whitehouse Laboratories ... its ICH Stability Testing and Package Test Capacity. Responding ... centers on a dramatic increase in environmental chamber storage ... stability, storage and aging samples to be securely held ... this major capital expenditure has already taken place with ...
Breaking Biology Technology:GuideWell Innovation Center Groundbreaking Hosted by Tavistock Development Company at Lake Nona Medical City 2GuideWell Innovation Center Groundbreaking Hosted by Tavistock Development Company at Lake Nona Medical City 3Ardelyx to Report Third Quarter 2014 Financial Results on November 6, 2014 2SoundConnect Launches Voice Enablement and Hybrid Audio Conferencing for Office 365 2SoundConnect Launches Voice Enablement and Hybrid Audio Conferencing for Office 365 3Whitehouse Labs Announces Major Capital Investment in Stability and Storage Testing Capacity 2Whitehouse Labs Announces Major Capital Investment in Stability and Storage Testing Capacity 3
... an important role in many cases of Parkinson,s disease (PD). ... Journal of Neuroscience , researchers from the Ecole Polytechnique ... model for studying a specific gene mutation commonly found in ... the malady. , "This is a great step forward toward ...
... shed water so effectively that they don,t need wipers. ... the water more efficiently than ordinary hulls. These are ... the hottest new materials in the field of nanotechnology, ... of physics at Vanderbilt. Dickerson and his colleagues have ...
... SAN MARINO, Calif., Feb. 1, 2011 Boston-based ... (Pink Sheets: VRAL ) and published ... on the company,s website at www.viralgenetics.com/investors/press-releases/R20Report ... through institutional platforms including FactSet, CapitalIQ, and TheMarkets.com. ...
Cached Biology Technology:A new model for studying Parkinson's 2Tuning graphene film so it sheds water 2Research 2.0 Initiates Coverage of Viral Genetics and Publishes Research Report 2Research 2.0 Initiates Coverage of Viral Genetics and Publishes Research Report 3
(Date:10/29/2014)... is open for the Society of Interventional ... 2015 is the one place where interventional ... health care professionals can come together to ... technologies being presented, discussed and tested. ... invasive, image-guided medicine, SIR 2015 will feature ...
(Date:10/29/2014)... to make their food, but they also need protection from ... a group of molecules in plants that shields them from ... of the American Chemical Society , one team reports on ... Timothy Zwier and colleagues at Purdue University note that the ... serious damage to plant DNA and, as a result, hinder ...
(Date:10/29/2014)... all the rage. Thousands of scientists worldwide are conducting ... titanium dioxide nanoparticles from sun creams can get through ... from electronic products are as hazardous for the lungs ... food can get into the blood via the intestinal ... are flowing – and the number of scientific projects ...
Breaking Biology News(10 mins):SIR 2015: Interventional radiology shapes tomorrow's medicine 2Nanosafety research: The quest for the gold standard 2Nanosafety research: The quest for the gold standard 3
... in the most exciting and unsettling period in the ... in public. On the one hand, the ... the psychiatric diagnostic manual, DSM-V, representing the current best ... categorize the enormously complex pattern of human emotional, cognitive, ...
... University of Adelaide has shown for the first time ... greatly increasing the risk of complications for themselves and their unborn ... world, researchers from the University,s Robinson Institute compared data ... results have been published online ahead of print in the ...
... time that the blood vessels that transport blood to and ... just bodily pipelines. Arterioles and capillaries, the small vessels, actually ... blood they,re carrying. Biomedical engineers at Drexel University, who study ... how they do it. The team, which includes Drs. ...
Cached Biology News:What is the brain telling us about the diagnoses of schizophrenia and bipolar disorder? 2Smoking + asthma + pregnant = a dangerous combination 2Drexel researchers looking inside vessels to understand blood's ebb and flow 2
capacity 250 mL...
... to MSY2/YBOX2 ( Abpromise for ... Antigen: Synthetic peptide derived from ... of human YBX2. (Note: the ... Entrez ...
... CLS number is a ... to easily match Cornings ... no availability yet, please ... Sigma-Aldrich number (Z35,347-7) or ...
Standard Fluka For microscopy (Bact., Hist.)...
Biology Products: